HealthQuill Japan
Bain Capital, a US-based private investment company, will buy the pharmaceutical arm of the Mitsubishi Chemical Group Corp. for $3.3 billion, according to the Massachusetts-based firm.
Drugs Health Medical

Bain Capital to buy Japan’s Mitsubishi Tanabe Pharma for $3.3 billion

Bain Capital, a US-based private investment company, will buy the pharmaceutical arm of the Mitsubishi Chemical Group Corp. for $3.3 billion, according to.

Read More
Anglo-Swedish AstraZeneca Plc., and Japan’s Daiichi Sankyo’s therapy to treat a certain form of breast cancer has been approved by the US drug regulator in the adult population. 
Drugs Health Pharma

AstraZeneca-Daiichi’s breast cancer drug gets broader US nod

Anglo-Swedish AstraZeneca Plc., and Japan’s Daiichi Sankyo’s therapy to treat a certain form of breast cancer has been approved by the US drug.

Read More
Biogen Inc. and its Japanese partner, Eisai Co. Ltd., announced that the US regulator had approved four-weekly maintenance dosing for its Alzheimer's drug.
Drugs Health Medical Pharma

Biogen-Eisai’s Alzheimer’s drug gets 4-weekly dosing nod in US

Biogen Inc. and its Japanese partner, Eisai Co. Ltd., announced that the US regulator had approved four-weekly maintenance dosing for its Alzheimer's drug.

Read More
Daiichi Sankyo, the second-largest pharmaceutical company in Japan in terms of revenue, has set up a laboratory in the US for robotic development, automation and software.
Drugs Health Pharma

Daiichi Sankyo sets up robotic lab in US to speed up drug discovery

Daiichi Sankyo, the second-largest pharmaceutical company in Japan in terms of revenue, has set up a laboratory in the US for robotic development,.

Read More
The European Union regulators have greenlighted AstraZeneca’s drug to treat an advanced form of non-small cell lung cancer after it reduced the death rate by 84%.
Drugs Medical Pharma

EU greenlights AstraZeneca’s non-small cell lung cancer drug

The European Union regulators have greenlighted AstraZeneca’s drug to treat an advanced form of non-small cell lung cancer after it reduced the death.

Read More
The US regulator has approved AstraZeneca’s blockbuster drug Imfinzi to treat adults with limited-stage cell lung cancer.
Drugs Medical Pharma

AstraZeneca’s drug gets nod to treat limited-stage cell lung cancer patients

The US regulator has approved AstraZeneca’s blockbuster drug Imfinzi to treat adults with limited-stage cell lung cancer.

Read More
AstraZeneca Plc’s drug Fasenra got approval from the European Union regulator for treating adult patients with a rare inflammation of blood vessels.
Drugs Health Pharma

AstraZeneca’s drug to treat rare blood vessel disease gets EU nod

AstraZeneca Plc’s drug Fasenra got approval from the European Union regulator for treating adult patients with a rare inflammation of blood vessels.

Read More
Astellas Pharma Inc.’s therapy to treat a form of gastric cancer got approval from the US drug regulator, according to a company statement.
Drugs Health Pharma

Astellas Pharma gets US regulator’s nod for its gastric cancer drug 

Astellas Pharma Inc.’s therapy to treat a form of gastric cancer got approval from the US drug regulator, according to a company statement.

Read More
Regeneron Pharmaceuticals and Sanofi’s drug, Dupixent, got the US regulator’s approval to treat patients with chronic obstructive pulmonary disease.
Drugs Health Pharma

Regeneron-Sanofi’s drug for lung disease gets US approval

Regeneron Pharmaceuticals and Sanofi’s drug, Dupixent, got the US regulator’s approval to treat patients with chronic obstructive pulmonary disease.

Read More
The US Food and Drug Administration approved AstraZeneca Plc’s Fasenra for treatment in adult patients with a rare inflammation of blood vessels.
Drugs Health Pharma

AstraZeneca’s rare disease drug Fasenra gets US regulator’s nod

The US Food and Drug Administration approved AstraZeneca Plc’s Fasenra for treatment in adult patients with a rare inflammation of blood vessels.

Read More